Validation of an enzyme-linked immunosorbent assay (ELISA) for the measurement of canine S100A12.
Additional Document Info
BACKGROUND: Canine S100 calcium-binding protein A12 (cS100A12) shows promise as biomarker of inflammation in dogs. A previously developed cS100A12-radioimmunoassay (RIA) requires radioactive tracers and is not sensitive enough for fecal cS100A12 concentrations in 79% of tested healthy dogs. An ELISA assay may be more sensitive than RIA and does not require radioactive tracers. OBJECTIVE: The purpose of the study was to establish a sandwich ELISA for serum and fecal cS100A12, and to establish reference intervals (RI) for normal healthy canine serum and feces. METHODS: Polyclonal rabbit anti-cS100A12 antibodies were generated and tested by Western blotting and immunohistochemistry. A sandwich ELISA was developed and validated, including accuracy and precision, and agreement with cS100A12-RIA. The RI, stability, and biologic variation in fecal cS100A12, and the effect of corticosteroids on serum cS100A12 were evaluated. RESULTS: Lower detection limits were 5 g/L (serum) and 1 ng/g (fecal), respectively. Intra- and inter-assay coefficients of variation were 4.4% and 10.9%, respectively. Observed-to-expected ratios for linearity and spiking recovery were 98.2 9.8% (mean SD) and 93.0 6.1%, respectively. There was a significant bias between the ELISA and the RIA. The RI was 49-320 g/L for serum and 2-484 ng/g for fecal cS100A12. Fecal cS100A12 was stable for 7 days at 23, 4, -20, and -80C; biologic variation was negligible but variation within one fecal sample was significant. Corticosteroid treatment had no clinically significant effect on serum cS100A12 concentrations. CONCLUSIONS: The cS100A12-ELISA is a precise and accurate assay for serum and fecal cS100A12 in dogs.